In-depth Characterization of Atriogenic Secondary Tricuspid Regurgitation Due to Atrial Fibrillation
Launched by ISTITUTO AUXOLOGICO ITALIANO · Feb 28, 2023
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a heart condition called secondary tricuspid regurgitation, which can happen in people with atrial fibrillation (a common heart rhythm problem). The study will involve 1,050 patients who have persistent or permanent atrial fibrillation. Researchers will use special heart imaging techniques to understand how often this heart valve issue occurs in these patients and what causes it. They will also look at blood tests to find out if certain proteins in the blood can help protect against this condition. Additionally, the trial will investigate how restoring a normal heart rhythm affects the severity of the tricuspid valve issue and the overall shape and function of the right side of the heart.
To participate in this study, individuals must be over 18 years old, have persistent or permanent atrial fibrillation, and meet specific health criteria, such as having a good heart function and no significant issues with other heart valves. Participants will undergo various tests and follow-up visits, where they will have their heart health closely monitored. This trial is currently recruiting participants, and it is open to everyone, regardless of gender. If you're considering joining, you'll need to sign a consent form to acknowledge your understanding of the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age\> 18 years
- • persistent/permanent atrial fibrillation
- • good acoustic apical window
- • left ventricular ejection fraction \> 50%
- • pulmonary artery systolic pressure\< 50 mm Hg
- • no more than mild mitral or aortic valve disease
- • ability to attend clinical and echocardiographic follow-ups
- • signature of the study informed consent
- Exclusion Criteria:
- • pregnancy
- • implanted pace-maker or ICD
- • previous heart valve surgery or transcatheter treatment
- • previous heart transplant
- • organic tricuspid regurgitation
About Istituto Auxologico Italiano
Istituto Auxologico Italiano is a prominent Italian research institute dedicated to advancing medical science and improving patient care through innovative clinical research. With a strong focus on metabolic diseases, cardiovascular health, and neuropsychological disorders, the institute integrates clinical practice with cutting-edge research to foster the development of new therapeutic strategies. Committed to ethical standards and patient safety, Istituto Auxologico Italiano collaborates with various national and international partners, contributing significantly to the global medical community while ensuring high-quality care and support for its patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milan, , Italy
Milan, , Italy
Milan, Select A State, Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials